MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Altimmune Inc

Slēgts

4.78 0.21

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.64

Max

4.95

Galvenie mērījumi

By Trading Economics

Ienākumi

-335K

-23M

Pārdošana

5K

EPS

-0.33

Peļņas marža

-463,600

Darbinieki

59

EBITDA

-344K

-23M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+361.18% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 8. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-16M

410M

Iepriekšējā atvēršanas cena

4.57

Iepriekšējā slēgšanas cena

4.78

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Altimmune Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 2. apr. 23:55 UTC

Karstas akcijas

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2025. g. 2. apr. 22:50 UTC

Galvenie tirgus virzītāji

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2025. g. 2. apr. 21:08 UTC

Peļņas

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2025. g. 2. apr. 21:00 UTC

Peļņas

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2025. g. 2. apr. 23:56 UTC

Tirgus saruna

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2025. g. 2. apr. 23:44 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 2. apr. 23:44 UTC

Tirgus saruna

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2025. g. 2. apr. 23:44 UTC

Top Ziņas

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2025. g. 2. apr. 23:32 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 2. apr. 23:32 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 2. apr. 23:32 UTC

Tirgus saruna

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2025. g. 2. apr. 23:12 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 2. apr. 23:12 UTC

Tirgus saruna

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2025. g. 2. apr. 23:10 UTC

Tirgus saruna

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2025. g. 2. apr. 23:09 UTC

Tirgus saruna

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2025. g. 2. apr. 23:09 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 2. apr. 22:57 UTC

Tirgus saruna

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2025. g. 2. apr. 22:56 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 2. apr. 22:56 UTC

Tirgus saruna

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2025. g. 2. apr. 22:43 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2025. g. 2. apr. 22:12 UTC

Tirgus saruna

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2025. g. 2. apr. 21:48 UTC

Top Ziņas

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2025. g. 2. apr. 21:41 UTC

Tirgus saruna

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2025. g. 2. apr. 21:17 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 2. apr. 21:17 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 2. apr. 21:17 UTC

Tirgus saruna

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2025. g. 2. apr. 21:04 UTC

Top Ziņas

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2025. g. 2. apr. 21:03 UTC

Tirgus saruna

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2025. g. 2. apr. 20:53 UTC

Peļņas

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2025. g. 2. apr. 20:52 UTC

Peļņas

Kaiser Aluminum Changes Inventory Acctg Methodology

Salīdzinājums

Cenas izmaiņa

Altimmune Inc Prognoze

Cenas mērķis

By TipRanks

361.18% augšup

Prognoze 12 mēnešiem

Vidējais 21.86 USD  361.18%

Augstākais 28 USD

Zemākais 12 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Altimmune Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

7

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 5.88Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.